LA
REGN icon

Legacy Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Legacy Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$276K Buy
435
+73
+20% +$50.2K 0.03% 349
2024
Q4 		$258K Buy
362
+64
+21% +$53.7K 0.03% 335
2024
Q3 		$313K Buy
298
+70
+31% +$77.9K 0.03% 293
2024
Q2 		$240K Buy
228
+20
+10% +$19.4K 0.03% 287
2024
Q1 		$200K Buy
+208
New +$198K 0.03% 304
2017
Q4 		– Sell
-20
Closed -$8K – 414
2017
Q3 		$8K Buy
+20
New +$9.52K 0.01% 240

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Legacy Advisors's REGN Position: Q1 2025 in Review

Legacy Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 20% in Q1 2025, buying an estimated $50.2K and bringing the position to 435 shares worth $276K. The position accounts for 0.03% of the portfolio, ranked #349.

Legacy Advisors first reported a position in REGN in Q3 2017 and has held it in 6 quarters since. The position peaked at $313K in Q3 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Legacy Advisors held 435 shares of Regeneron Pharmaceuticals worth $276K as of Q1 2025.
  • Legacy Advisors bought 73 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $50.2K.
  • Regeneron Pharmaceuticals made up 0.03% of Legacy Advisors's portfolio in Q1 2025, its #349 holding.
  • Legacy Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 6 quarters since.
  • Legacy Advisors's Regeneron Pharmaceuticals position peaked at $313K in Q3 2024.
  • 1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Legacy Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.